SEATTLE and REDWOOD CITY, Calif.--(BUSINESS WIRE)--March 13, 2006--Rosetta Biosoftware announced today that FoxHollow Technologies has licensed the Rosetta Resolver(R) system for research on cardiovascular disease. FoxHollow Technologies developed and markets the SilverHawk(TM) Plaque Excision System, an atherosclerotic plaque excision device approved in the U.S. for the treatment of peripheral arterial disease (PAD). The Biologicals Division at FoxHollow will use the Resolver application to correlate genetic profiles of human atherosclerotic plaque samples with clinical findings as a tool for the development and evaluation of therapies targeted at atherosclerosis.
